Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden.
Novo Nordisk Foundation Center for Biosustainability, Chalmers University of Technology, Gothenburg, Sweden.
Microb Cell Fact. 2021 Jul 14;20(1):134. doi: 10.1186/s12934-021-01624-0.
Monoclonal antibodies, antibody fragments and fusion proteins derived thereof have revolutionized the practice of medicine. Major challenges faced by the biopharmaceutical industry are however high production costs, long processing times and low productivities associated with their production in mammalian cell lines. The yeast Saccharomyces cerevisiae, a well-characterized eukaryotic cell factory possessing the capacity of post-translational modifications, has been industrially exploited as a secretion host for production of a range of products, including pharmaceuticals. However, due to the incompatible surface glycosylation, few antibody molecules have been functionally expressed in S. cerevisiae. Here, three non-glycosylated antibody fragments from human and the Camelidae family were chosen for expression in a S. cerevisiae strain (HA) previously evolved for high α-amylase secretion. These included the Fab fragment Ranibizumab (Ran), the scFv peptide Pexelizumab (Pex), and a nanobody consisting of a single V-type domain (Nan). Both secretion and biological activities of the antibody fragments were confirmed. In addition, the secretion level of each protein was compared in the wild type (LA) and two evolved strains (HA and MA) with different secretory capacities. We found that the secretion of Ran and Nan was positively correlated with the strains' secretory capacity, while Pex was most efficiently secreted in the parental strain. To investigate the mechanisms for different secretion abilities in these selected yeast strains for the different antibody fragments, RNA-seq analysis was performed. The results showed that several bioprocesses were significantly enriched for differentially expressed genes when comparing the enriched terms between HA.Nan vs. LA.Nan and HA.Pex vs. LA.Pex, including amino acid metabolism, protein synthesis, cell cycle and others, which indicates that there are unique physiological needs for each antibody fragment secretion.
单克隆抗体、抗体片段及其衍生的融合蛋白彻底改变了医学实践。然而,生物制药行业面临的主要挑战是高生产成本、长处理时间以及与其在哺乳动物细胞系中的生产相关的低生产率。酵母酿酒酵母是一种经过充分表征的真核细胞工厂,具有翻译后修饰的能力,已被工业上用作一系列产品(包括药物)生产的分泌宿主。然而,由于表面糖基化不兼容,很少有抗体分子在酿酒酵母中具有功能性表达。在这里,选择了来自人类和骆驼科家族的三种非糖基化抗体片段在先前为高α-淀粉酶分泌而进化的酿酒酵母菌株 (HA) 中进行表达。这些片段包括 Ranibizumab (Ran) 的 Fab 片段、Pexelizumab (Pex) 的 scFv 肽和由单个 V 型结构域组成的纳米抗体 (Nan)。均证实了抗体片段的分泌和生物学活性。此外,还比较了每种蛋白质在具有不同分泌能力的野生型 (LA) 和两种进化株 (HA 和 MA) 中的分泌水平。我们发现,Ran 和 Nan 的分泌与菌株的分泌能力呈正相关,而 Pex 在亲本菌株中分泌效率最高。为了研究这些选定的酵母菌株对不同抗体片段具有不同分泌能力的机制,进行了 RNA-seq 分析。结果表明,当比较 HA.Nan 与 LA.Nan 和 HA.Pex 与 LA.Pex 之间富集的术语时,几个生物过程在差异表达基因中显著富集,包括氨基酸代谢、蛋白质合成、细胞周期等,这表明每个抗体片段的分泌都有独特的生理需求。